Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
Go back to Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome| Marina Biotech, Inc. (NASDAQ: MRNA) | Delayed: 61.00 +1.65 (2.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $59.35 | 52 Week High | $0.52 | |||
| Open | $59.05 | 52 Week Low | $0.08 | |||
| Day High | $63.98 | P/E | N/A | |||
| Day Low | $58.34 | EPS | $-3.80 | |||
| Volume | 6,831,157 | |||||
